Results 251 to 260 of about 119,936 (354)

Fluoropyrimidine-induced cardiotoxicity: outcomes and safety of chemotherapy reintroduction in a retrospective cohort study. [PDF]

Support Care Cancer
Réa O, Bouali A, Serraille M, Péron J, Falandry C, Fort J, François L, Harbaoui B, Lantelme P, Courand PY.   +9 more
europepmc   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender, Lauren Pommert, Lori R. Backus, Andrea Bidwell, Courtney Blank, Erin H. Breese, Karen C. Burns, Adam Lane, Lynn H. Lee, Benjamin Mizukawa, Robin E. Norris, Maureen M. O'Brien, Daniel Peck, Christine Phillips, Thomas D. Ryan, Jennifer Young, Michael Absalon, John P. Perentesis   +17 more
wiley   +1 more source

Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management. [PDF]

Front Pharmacol
Xiao L, Lin X, Yang Z, Lin B, Xie R.
europepmc   +1 more source

Decision-making in interstitial stem cells of hydra [PDF]

, 1991
Bosch, Thomas C. G., David, Charles N.
core  

Chronic Low‐Dose Unsymmetrical Dimethylhydrazine Exposure in Rats: Multiorgan Mechanisms and Biomarker Identification

Journal of Applied Toxicology, Volume 46, Issue 6, Page 1987-2002, June 2026.
ABSTRACT Unsymmetrical dimethylhydrazine (UDMH), a highly toxic rocket propellant with known multiorgan effects, requires urgent characterization of its chronic low‐dose toxicity. Using an integrated approach including exploratory transcriptomics (n = 3/group) and metabolomic (n = 4/group) approaches in male Sprague–Dawley rats exposed to high‐dose ...
Fuzhou Liu, Bing Liu, Keli Wang, Xiaoyu Wang, Zhen Sun, Xiaojuan Pan, Zengming Zhao   +6 more
wiley   +1 more source

An echocardiographic study of right ventricular function and pulmonary systolic pressure in patients treated with anthracyclines. [PDF]

J Cardiovasc Imaging
Ozan R, Elçik D, Demiray A, Zengin İ, Abibulaev E, Yurt R, Ulaş O, Düzgün İ, Aslan AÇ, Inanç M, Oğuzhan A.   +10 more
europepmc   +1 more source

Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management

Journal of Applied Toxicology, Volume 46, Issue 6, Page 1856-1870, June 2026.
ABSTRACT Ivermectin is a widely used macrocyclic lactone with established efficacy against a broad range of parasitic infections in humans and animals and a long‐standing reputation for clinical safety. However, increasing evidence indicates that ivermectin can produce clinically relevant toxicity under specific conditions, particularly involving the ...
Serkan Yilmaz, Bayram Göktaş, İlker Ateş, Mustafa Çelik   +3 more
wiley   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

Integrating network toxicology, machine learning, and molecular dynamics simulations to reveal tanshinone iia's dual mechanisms in TNBC and doxorubicin-induced cardiotoxicity. [PDF]

Sci Rep
Wu B, Lan XH, Chen XQ, Wu QY, Yu ZY, Wang YK, Yang Y, Cao XC, Wang XD, Zhou SY, Lin L.   +10 more
europepmc   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 381-391, June 2026.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source